Deerfield Management Company, L.P. (Series C) Ionis Pharmaceuticals Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,979,669 shares of IONS stock, worth $142 Million. This represents 2.41% of its overall portfolio holdings.
Number of Shares
1,979,669Holding current value
$142 Million% of portfolio
2.41%Shares
1 transactions
Others Institutions Holding IONS
# of Institutions
507Shares Held
155MCall Options Held
2.69MPut Options Held
1.03M-
Vanguard Group Inc Valley Forge, PA16.5MShares$1.18 Billion0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD13.2MShares$941 Million0.53% of portfolio
-
Capital World Investors Los Angeles, CA12.7MShares$910 Million0.12% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$738 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.59MShares$471 Million0.08% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $10.2B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...